Hepatitis C virus (HCV) infection is a major cause of
|
|
- Augustine Powers
- 5 years ago
- Views:
Transcription
1 CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6: Clinical Significance of Metabolic Syndrome in the Setting of Chronic Hepatitis C Virus Infection IBRAHIM A. HANOUNEH,* ARIEL E. FELDSTEIN, ROCIO LOPEZ, LISA YERIAN, ANJANA PILLAI, CLAUDIA O. ZEIN, # and NIZAR N. ZEIN *Department of Internal Medicine, Department of Gastroenterology and Hepatology, Department of Pediatric Gastroenterology and Cell Biology, Department of Quantitative Health Sciences, and the Department of Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio; and the # Department of Gastroenterology and Hepatology, Case Western Reserve University, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio See Korenblat KM et al on page 1369 for companion article in the May 2008 issue of Gastroenterology. Background & Aims: The metabolic syndrome (MS) is a unique condition in which the underlying mechanism is related to insulin resistance. In hepatitis C virus (HCV) patients, insulin resistance has been linked to treatment failure. The aim of this study was to estimate the prevalence of MS in HCV patients undergoing antiviral therapy and to assess its predictive value in treatment outcome. Methods: All HCV treatment-naive patients who met the inclusion/ exclusion criteria were studied (n 228). MS was defined using the National Cholesterol Education Program Adult Treatment Panel III criteria. A logistic regression analysis was performed to study multivariable associations. The final model contained sex, ethnicity, body mass index, viral load, genotype, steatosis, fibrosis stage, and MS. Results: MS was present in 59 of 228 (26%) patients. Genotype 1 (P.002) and presence of steatosis (P <.001) were found to be associated significantly with MS. Overall, sustained virologic response (SVR) was achieved in 108 of 228 (47%) patients. Male sex, non-caucasian ethnicity, higher body mass index, high viral load, genotype 1, higher fibrosis stage, and MS were associated significantly with a lack of SVR. After adjusting for confounding variables, MS remained independently associated with a lack of SVR (P <.01). Specifically, subjects with MS were 3.8 (95% confidence interval, ) times more likely to fail treatment than those without MS. Conclusions: MS is seen frequently in patients with chronic HCV and is associated independently to lack of SVR. These findings support the concept that an aggressive intervention approach comprising lifestyle modification alone or in combination with drug treatment of the MS components may play an important role in improving antiviral responses in these patients. Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma throughout the world. Despite significant advances in knowledge of HCV biology and pathogenesis, a considerable number of infected patients will fail to achieve viral eradication after antiviral therapy and may develop complications of endstage liver disease. 1,2 The metabolic syndrome (MS), characterized by a constellation of factors including obesity, impaired fasting glucose, hypertension, and dyslipidemia, has become a major public health problem in the United States and many other parts of the world. A growing body of evidence suggests that several components of the MS may be important cofactors in chronic HCV-infected patients. 3,4 Insulin resistance (IR), the common denominator in the MS, has been shown extensively to be associated with chronic HCV infection with data supporting both viral- and host-mediated contributions. 5 A recent study using a mouse model transgenic for HCV core gene provided experimental evidence for a direct involvement of HCV in the development of IR and its associated hyperinsulinemia. 6 Moreover, IR measured by a homeostasis model of assessment (HOMA) has been implicated in the development of steatosis and progression of fibrosis in patients with chronic HCV Analogous to proposed mechanisms of hepatic fibrosis in patients with nonalcoholic steatohepatitis, hyperinsulinemia in HCV patients potentially may promote fibrogenesis through altered cytokine production including tumor necrosis factor alpha or by its direct effect on hepatic stellate cells. 11 In addition, IR has been linked to resistance to antiviral therapy in patients with chronic HCV infection, particularly those with HCV genotype 1. From the results of several cohort studies, it has been recognized that IR measured by HOMA is associated independently with poor response to antiviral therapy. In one prospective study, sustained virologic response (SVR) was only 36% in HCV genotype 1 patients with HOMA greater than 2 (IR) compared with an SVR rate of 49% in those with HOMA less than 2 (no IR). 12 Although the relationship between chronic HCV infection and IR has been shown both experimentally and in human studies, the association between HCV and MS remains poorly understood and the impact of MS on disease progression and treatment outcome in HCV patients has not been assessed carefully. MS is of particular interest because of its increasing prevalence among adults and children alike and for its potentially preventable and modifiable nature. Abbreviations used in this paper: BMI, body mass index; CI, confidence interval; DM, diabetes mellitus; HCV, hepatitis C virus; HDL, highdensity lipoprotein; HOMA, homeostasis model of assessment; HVL, high baseline viral load; IR, insulin resistance; MS, metabolic syndrome; PEG IFN, pegylated interferon; Q25 Q75, 25 th percentile 75 th percentile; RBV, ribavirin; SVR, sustained virologic response by the AGA Institute /08/$34.00 doi: /j.cgh
2 May 2008 METABOLIC SYNDROME IN HCV 585 It is estimated that 22% of US adults 20 years or older meet the diagnostic criteria of MS. 15,16 The specific aims of this study were to estimate the prevalence of MS in our patients with chronic HCV undergoing therapy, to assess the interaction between MS and histologic findings, and to evaluate the predictive value of MS as an independent factor in identifying those who are likely to fail antiviral treatment. Patients and Methods Patient Population and Data Collection We identified all adult patients (age, 18 y) with chronic HCV infection who were treated for the first time with pegylated interferon (PEG IFN)-alfa and ribavirin (RBV) combination therapy at the Cleveland Clinic in Cleveland, Ohio, between 2002 and Patients with insufficient data to establish the presence or absence of MS at the initiation of antiviral therapy were excluded. MS was defined according to the National Cholesterol Education Program, Adult Treatment Panel III 16 as the presence of any 3 of the following 5 criteria: (1) serum triglyceride levels greater than 150 mg/dl or drug treatment for increased triglyceride levels; (2) serum high-density lipoprotein (HDL) cholesterol less than 40 mg/dl in men or less than 50 mg/dl in women, or drug treatment for low HDL; (3) blood pressure greater than 130/85 mm Hg or drug treatment for increased blood pressure; (4) fasting plasma glucose greater than 110 mg/dl or drug treatment for increased blood glucose levels; (5) abdominal obesity, defined as a waist circumference in men greater than 102 cm (40 inches), and in women greater than 88 cm (35 inches). The last trait in the Adult Treatment Panel III criteria (waist circumference) was replaced by body mass index (BMI) greater than 28.8 kg/m 2 in both men and women for the purpose of this study. This cut-off value for BMI was equivalent in a regression analysis to a waist circumference of 102 cm in a cross-sectional study. 17 Patients were excluded if they had received previous antiviral therapy for HCV. Patients who received PEG-IFN monotherapy or non PEG IFN with or without RBV were excluded. We also excluded subjects with other confounding liver diseases including autoimmune hepatitis, hemochromatosis, primary biliary cirrhosis, Wilson s disease, 1-antitrypsin deficiency, and neoplasia. Patients with hepatitis B or human immunodeficiency virus co-infection were not included in this study. All patients had no or minimal alcohol intake at the time of HCV therapy. Patients also were excluded if they were receiving corticosteroids, total parenteral nutrition or methotrexate, amiodarone, and valproic acid. Demographic data (age, sex, and race/ethnicity), pretreatment BMI, fasting serum glucose, triglyceride and HDL levels, systolic and diastolic blood pressure, HCV RNA level, HCV genotype, and liver histology were extracted from prospectively collected data for patients with chronic HCV infection seen at the Cleveland Clinic. Detailed medical history including a history of hypertension, hyperlipidemia, and diabetes, and their corresponding therapy were obtained from medical records. In addition, the cumulative dose of PEG IFN and RBV received, timing and reasons for dose reductions and discontinuations, occurrence of adverse events, and use of growth factors and antidepressants were obtained from HCV treatment-related data sheets filled out prospectively in all patients undergoing therapy. Antiviral Treatment Regimen Standard Food and Drug Administration approved dose regimens of PEG IFN alfa-2a (180 mcg/wk) or PEG IFN alfa-2b (1.5 mcg/kg/wk) and ribavirin (1000 mg/d if patient weight 75 kg, and 1200 mg/d if 75 kg) were initiated in all patients. Dose reductions and the use of growth factors were permitted for the management of anemia, neutropenia, and thrombocytopenia. Filgrastim 300 mcg weekly was used when the absolute neutrophil count decreased to less than 500/L. If the neutrophil count persisted below these limits, PEG IFN would be reduced. The PEG-IFN dose also was reduced for a platelet count of less than 30,000/L, and discontinued if platelet counts were less than 25,000/L. Erythropoietin 40,000 U subcutaneously was administrated once weekly if the hemoglobin level decreased to less than 10 g/dl. RBV dose was reduced by 200 mg if there was no improvement, and discontinued for hemoglobin less than 8 g/dl. Peg/RBV also were reduced or discontinued for disabling fatigue or severe depression not responsive to antidepressant therapy. Treatment duration was 48 weeks for patients with genotypes 1 and 4, and 24 weeks for genotypes 2 and 3. Treatment was discontinued in genotype 1 patients who did not have early virologic response at week 12 of therapy (defined by negative HCV RNA, or 2-log decrease in HCV RNA from pretreatment viral load). Hepatitis C Virus RNA and Laboratory Assays Quantitative polymerase chain reaction assay (Cobas Amplicor HCV Monitor Test, v 2.0; Roche, Nutley, NJ) was performed to detect HCV RNA at weeks 0, 12, 24, and 48 of therapy. Qualitative HCV RNA (Amplicor; Roche) testing was performed for those with an undetectable HCV RNA by qualitative assay at any time during therapy to confirm negativity of HCV RNA. For patients who were HCV RNA negative at the end of treatment, HCV RNA was repeated 6 months later to establish or exclude SVR. High baseline viral load (HVL) in this study was defined as an HCV RNA level that is greater than 800,000 IU/mL. Complete blood count was performed weekly for 1 month, and, if stable, on a monthly basis until the end of treatment. Liver function tests were performed monthly until end of treatment. Fasting serum glucose, plasma triglyceride and HDL levels, systolic and diastolic blood pressure, and BMI were measured at least twice before antiviral therapy and the average values were used to identify those with MS according to the Adult Treatment Panel III criteria. Liver Histology Liver biopsy was performed at least 1 month before the start of therapy. Hepatic steatosis was quantified as the percentage of hepatocytes that contained fat droplets, and accordingly assigned as negative when less than 5% of hepatocytes contained fat droplets, and positive when greater than 5% of hepatocytes showed fat storage. Hepatic fibrosis (stage) was assessed by the Ludwig Batts scoring system, and accordingly assigned using a scale of 0 to 4 (F0, absent; F1, portal fibrosis; F2, focal bridging fibrosis; F3, marked bridging fibrosis; F4, cirrhosis).
3 586 HANOUNEH ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 6, No. 5 Table 1. Baseline Clinical Characteristics in Study Patients Compared With Patients Who Were Excluded From the Study Characteristic Study patients (n 228) Excluded patients (n 173) P value Age a 52 (47 55) 51 (48 55).96 Caucasians 176 (77%) 134 (77%).95 Men 121 (53%) 102 (59%).24 Genotype (70.6%) 105 (69.9%).88 HVL 106 (46.5%) 78 (45.1%).78 BMI a 27.7 ( ) 28.3 ( ).48 Advanced hepatic fibrosis was defined as the presence of F3 or F4 according to the Ludwig Batts scoring system. Statistical Analysis Descriptive statistics were computed for all factors. These included median, 25th and 75th percentiles for continuous variables, and frequencies for categoric factors. The Wilcoxon rank-sum test was used to assess statistical differences in continuous or ordinal factors between subjects who achieved SVR and those who did not. For categoric factors, the Pearson chi-square or the Fisher exact tests were used. The same was performed to study associations with MS and advanced fibrosis (F3 and F4). A logistic regression analysis was performed to study multivariable associations. The final model for treatment failure included ethnicity, obesity, genotype, metabolic syndrome, HCV RNA, steatosis, and fibrosis. Statistical significance was considered for a P value of less than.05. SAS version 9.1 software (SAS Institute, Cary, NC) was used to perform all analyses. Results Patient Characteristics A total of 401 HCV patients were treated with antiviral medications during the time period from which study patients were identified. A total of 173 subjects (43%) were excluded for having one or more exclusion factors. Reasons for exclusion included previous antiviral treatment (n 23), type of therapy given (n 11), inadequate follow-up evaluation to establish the presence or absence of SVR (n 48), having other confounding liver disease or human immunodeficiency virus co-infection (n 21), and solid organ transplant recipients (n 7). Another reason for exclusion was missing pretreatment data to establish the diagnosis of MS (missing triglyceride/hdl values [n 34], missing BMI [n 12], missing fasting glucose level [n 14], or missing blood pressure [n 3]). To minimize a potential selection bias, we compared clinical characteristics of excluded patients with those who fulfilled inclusion/exclusion criteria. Demographic characteristics including age, race distribution, sex distribution, genotype, and pretreatment HCV RNA levels of 174 excluded patients were similar to the 228 patients included in the study (Table 1). The baseline characteristics of our study patients who fulfilled inclusion criteria are shown in Table 2. The median age was 52 years; and most (77%) were Caucasians with a predominant genotype 1 infection (70%). Baseline liver biopsy before initiation of antiviral therapy was available in 196 (84.2%) patients, with a median time of 5 months (25 th percentile 75 th percentile [Q25 Q75], 2 9 mo) between liver biopsy and initiation of antiviral therapy. Of 196 biopsy specimens, 104 (53%) had steatosis involving greater than 5% of the hepatocytes, and 52 (26.5%) had advanced fibrosis. High baseline HCV RNA levels (HVL) was present in 106 (46.5%) patients. Seventy-three patients (32%) were obese at the initiation of antiviral therapy (BMI, 30 kg/m 2 ), with a median BMI of 28.4 kg/m 2. In addition, 51 (22%) had either glucose intolerance or type II diabetes mellitus (DM). Prevalence of the Metabolic Syndrome and its Relation to Histologic Findings Fifty-nine of 228 (26%) patients met the Adult Treatment Panel III criteria for the MS (Table 2). Patients with HCV genotype 1 had a higher prevalence of the MS than those with genotypes other than 1 (51 of 161 [31%] vs 8 of 67 [12%]; P.002) (Table 2). There was a racial difference in the prevalence of the MS, with a higher prevalence of the MS in non-caucasian patients compared with Caucasian patients, although the difference did not reach statistical significance (P.1). Table 2. Clinical Features of Study Patients With or Without MS Factor All patients (N 228) MS (N 59) No MS (N 169) Odds ratio (95% CI) P value Age a 52.0 ( ) 53.0 ( ) 52.0 ( ) 1.3 ( ).07 Men (%) 121 (53) 32 (54.2) 89 (52.7) 1.07 ( ).83 Non-Caucasian (%) 52 (23) 18 (30.5) 34 (20.1) 1.7 ( ).1 Genotype 1 (%) 161 (70.6) 51 (86.4) 110 (65.1) 3.4 ( ).002 HVL (%) 106 (46.5) 24 (40.7) 82 (48.5) 0.73 ( ).3 BMI a 27.7 ( ) 31.8 ( ) 26.2 ( ) 1.3 ( ).001 Triglyceride level a 101 ( ) 167 ( ) 95.0 ( ) 1.2 ( ).001 HDL level a 50.0 ( ) 43.5 ( ) 51.0 ( ) 0.86 ( ).12 GIT and/or DM (%) 51 (22.4) 41 (69.5) 10 (5.9) 36.2 ( ).001 Hypertension (%) 119 (52.2) 56 (94.9) 63 (37.3) 31.4 ( ).001 Steatosis (%) 104 (53.1) 39 (73.6) 65 (45.5) 3.3 ( ).001 Advanced fibrosis (%) 52 (26.5) 19 (35.9) 33 (23.1) 1.9 ( ).072 NOTE. Odds ratio for age corresponds to a 5-year increase, and odds ratio for triglyceride and HDL levels correspond to a 10-unit increase. GIT, glucose intolerance.
4 May 2008 METABOLIC SYNDROME IN HCV 587 Table 3. Factors Associated With Advanced Fibrosis Factor Advanced fibrosis (n 52) Mild fibrosis (n 144) P value Age a 54.0 ( ) 50.0 ( ).001 Triglyceride level a ( ) ( ).55 HDL level a 52.5 ( ) 50.0 ( ).69 MS (%) 19 (36.5) 34 (23.6).072 Men (%) 31 (59.6) 77 (53.5).45 Caucasian (%) 37 (71.2) 113 (78.5).29 Genotype 1 33 (63.5) 110 (76.4).072 Obese (%) 17 (32.7) 45 (31.3).85 HVL (%) 26 (50.0) 65 (45.1).55 GIT and/or DM (%) 19 (36.5) 26 (18.1).007 Hypertension (%) 30 (57.7) 73 (50.7).39 Steatosis (%) 29 (55.8) 75 (52.1).65 GIT, glucose intolerance. The MS was associated significantly with the presence of steatosis in liver biopsy (Table 2). Steatosis was present in 39 of 59 (73.6%) HCV patients in whom MS criteria were met compared with 65 of 169 (45.5%) of those without MS (P.001). However, there was no association between steatosis and advanced fibrosis by either univariable or multivariable analysis (Tables 3 and 4). Univariable and multivariable analysis of factors associated with advanced fibrosis are shown in Tables 3 and 4. In univariable analysis (Table 3), advanced fibrosis was associated with age (P.001) and diabetes (P.007). In addition, a trend toward an association between advanced fibrosis and MS (P.072), as well as non genotype 1 infection (P.072) was present. However, after adjusting for these features in multivariable analysis (Table 4), MS was not associated with advanced fibrosis (P.57). Age (P.007), DM (P.052), and non genotype 1 (P.018) remained significantly related to advanced fibrosis. Response to Therapy and Predictors of Response Overall, SVR was achieved in 108 of 228 (47%) patients. Subjects with genotype 1 were less likely to achieve SVR compared with non genotype 1 patients (58 of 161 [36%] vs 50 of 67 [74%]; P.001) (Table 5). Relative to Caucasians, non- Caucasians had a lower response rate (lower SVR) to antiviral therapy (11 of 52 [21%] vs 97 of 176 [55%]; P.001). In addition, women were more likely to achieve SVR compared with their male counterparts (59 of 107 [55%] vs 49 of 121 [40%]; P.027). Other predictors of treatment failure by univariable analysis included older age, high pretreatment viral load (.007), advanced fibrosis (.002), DM (P.001), obesity (P.015), and MS (P.001) (Table 5). Multivariable logistic regression analysis of relevant variables showed that genotype 1 (P.0001), non-caucasian race (P.001), advanced fibrosis (P.002), and MS (P.009) had lower odds of achieving SVR than their corresponding counterparts (Table 6). After controlling for ethnicity, obesity, genotype, baseline HCV RNA, steatosis, and fibrosis, subjects with MS were 3.8 times (95% confidence interval [CI], ) more likely to fail treatment than those without MS. Obesity alone, although associated with a lack of SVR by univariable analysis, was not associated significantly with treatment outcome in the multivariable regression analysis model (P.68). The significance of obesity as an independent predictor of SVR did not change by using a cut-off point of 30 kg/m 2 to define obesity instead of 28.8 kg/m 2 (data not shown). The association between MS and lack of SVR was evident across different subgroups of patients. HCV genotype 1 patients with MS were less likely to achieve SVR than those without MS (SVR, 11 of 51 [21.6%] vs 47 of 110 [42.7%]; P.009). Similarly, subjects with advanced fibrosis and MS were less likely to achieve SVR compared with those who had advanced fibrosis without MS (SVR, 2 of 19 [10.5%] vs 12 of 33 [36.4%]; P.057]. Finally, only 2 of 19 (5.6%) African American patients with MS achieved SVR compared with 10 of 34 (29.4%) African American patients without MS (P.07). Discussion Several earlier studies established an epidemiologic association between HCV and DM. 18,19 More recently, IR in the absence of frank DM has been linked to the development of complications and failure of therapy in patients with chronic HCV ,20 In genotype 1 infection, the rate of SVR was nearly twice as common in patients who did not have evidence of IR by HOMA test compared with patients with IR. 12 An unresolved issue is the optimal method and its reproducibility to measure IR to identify those who are less likely to benefit from antiviral therapy in routine clinical practice. There is considerable variation in the complexity and intensity of various methods used to measure IR and no single test is appropriate under all circumstances. 21 Although the gold standard test to measure IR is the euglycemic clamp, it is only useful for intensive physiologic studies and is not feasible to incorporate into clinical practice. 21 Other methods to measure insulin sensitivity are those derived from oral glucose tolerance tests, in which they rely on the measurement of plasma glucose and insulin concentrations, either from fasting values (HOMA and quantitative insulin sensitivity index), 21 or postload values. 21 However, those methods are based on measurement of fasting blood insulin, which may vary considerably from one laboratory to another. 15 The so-called MS (also called insulin-resistance syndrome)isthe most commonly encountered clinical consequence of IR. MS is associated more consistently with the risk for cardiovascular disease than its individual components (obesity, diabetes, hypertension, and lipid abnormalities) and associated more consistently with measurable IR than its individual components. 15 MS also is incorporated easily into routine clinical practice with no need for sophisticated or expensive assays. Table 4. Multivariable Logistic Regression Analysis of Factors Associated With Advanced Hepatic Fibrosis Factor Odds ratio (95% CI) P value MS 1.4 ( ).57 Non-1 genotype 2.6 ( ).018 Age (5-year increase) 1.5 ( ).007 GIT and/or DM 3.0 ( ).052 Ethnicity (other vs Caucasian) 1.6 ( ).26 Obesity (BMI 30 kg/m 2 ) 2.2 ( ).13 GIT, glucose intolerance.
5 588 HANOUNEH ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 6, No. 5 Table 5. Univariable Analysis of Factors Associated With Treatment Failure Factor No SVR (N 120) SVR (N 108) Odds ratio (95% CI) P value Age a 53.0 ( ) 50.0 ( ) 1.3 ( ).001 Male (%) 72 (60.0) 49 (45.4) 1.8 ( ).027 Non-Caucasian (%) 41 (34.2) 11 (10.2) 4.6 ( ).001 Genotype 1 (%) 103 (85.8) 58 (53.7) 5.2 ( ).001 Baseline HVL (%) 66 (55.0) 40 (37.0) 2.1 ( ).007 Obese (%) 47 (39.2) 26 (24.1) 2.0 ( ).015 Triglyceride level a ( ) 95.0 ( ) 1.04 ( ).16 HDL level a 50.0 ( ) 50.0 ( ) 1.03 ( ).97 DM (%) 40 (33.3) 11 (10.2) 4.4 ( ).001 Hypertension (%) 73 (60.8) 46 (42.6) 2.1 ( ).006 MS (%) 44 (36.7) 15 (13.9) 3.6 ( ).001 Steatosis (%) 59 (54.6) 45 (51.1) 1.2 ( ).63 Advanced fibrosis (%) 38 (35.2) 14 (15.9) 2.9 ( ).002 NOTE. Odds ratio for age corresponds to a 5-year increase and odds ratio for triglyceride and HDL levels correspond to a 10-unit increase. In the current study, MS was present in 25% of patients with chronic HCV infection, which is slightly higher than the prevalence of MS (22%) reported in 8814 adults in the United States participating in the National Health and Nutrition Examination Survey III. 16 The higher prevalence of MS in our study may be owing to the ability of HCV to induce IR, predisposing infected patients to a greater risk for the development of MS. Alternatively, it may reflect the small sample size or geographic differences because our population was derived from the Midwest region of the United States. The higher prevalence of MS in patients with HCV genotype 1 infection compared with those infected with non-1 genotypes is interesting and may suggest a specific role of HCV genotype 1 virus in inducing metabolic abnormalities such as IR. 22 It has been shown previously that steatosis associated with HCV genotype 1 infection is a marker of metabolic abnormalities including obesity, hyperlipidemia, or DM and has been termed metabolic fat. 23,24 In contrast, steatosis in patients with HCV genotype 3 is associated with viremia rather than metabolic abnormalities and has been termed viral fat. 23,24 Our findings support the association between HCV genotype 1 infection and metabolic abnormalities in infected individuals. Adjusting for relevant variables, we found that neither MS nor steatosis on liver biopsy specimen were associated with advanced hepatic fibrosis. Conversely, DM was associated strongly with advanced fibrosis by univariable and multivariable analysis consistent with previous studies It has been shown previously that higher serum glucose levels as well as overt DM are associated with advanced liver fibrosis as well as Table 6. Predictors of Treatment Failure: Multivariable Logistic Regression Analysis Factor Odds ratio (95% CI) P value Genotype ( ).0001 Non-Caucasian ethnicity 4.8 ( ).001 Advanced fibrosis 4.2 ( ).002 MS 3.8 ( ).009 Baseline HVL 2.2 ( ).029 Obesity (BMI 30 kg/m 2 ) 0.83 ( ).68 Steatosis 1.04 ( ).92 a higher fibrosis progression rate. 28 The impact of DM/hyperglycemic state on the rate of fibrosis progression was greater than that of obesity, consistent with the findings in this study. 28 It is not clear why non genotype 1 infection was associated independently with advanced fibrosis compared with genotype 1 infection, although this also has been noted in other studies, particularly for patients infected with HCV genotype-3 virus. 29,30 A major limitation of our study design was that it was based on a cross-sectional, single-time biopsy specimen. Future studies of the impact of MS on fibrosis progression in the setting of HCV should include paired or multiple biopsy specimens obtained from each individual over a period of time to accurately control for the length of follow-up evaluation and to minimize the potential effect of sampling error. The most clinically significant finding of this study was the association between MS and treatment outcome in patients with chronic HCV. MS was associated significantly with the lack of SVR by univariable and multivariable analysis. Adjusting for ethnicity, genotype, obesity, baseline HCV RNA, steatosis, and fibrosis, subjects with MS were 3.8 (95% CI, ) times more likely to fail treatment than those without MS. Accordingly and given the simplicity of its assessment in the clinical practice, MS could be used along with other established predictors of treatment failure to identify those who are less likely to benefit from antiviral therapy. Other factors that were associated independently with lack of SVR in this study included genotype 1, non-caucasian ethnicity, advanced fibrosis stage, and HVL, all of which have been identified previously in retrospective and prospective studies. Of interest is that although obesity was associated with treatment failure by univariable analysis, it was not associated independently with treatment outcome, adding to the controversy in current medical literature regarding the role of obesity in treatment outcome of HCV patients. In population-based studies, it was suggested that MS is present in only 60% of obese individuals (BMI, 30), 31 which may explain discrepancies among studies. In summary, MS is seen frequently in patients with chronic HCV and is associated with treatment failure in the setting of chronic HCV. This finding, especially if validated in larger trials, suggests that MS may identify patients who are less likely to benefit from antiviral therapy. Future studies are underway to
6 May 2008 METABOLIC SYNDROME IN HCV 589 explore the role of interventions used in patients with MS including weight loss, lipid-lowering agents, and insulin-sensitizing agents as adjuvant to maximize SVR in HCV patients. References 1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347: Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358: Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002;36(Suppl 1):S47 S Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999;29: Bloomgarden ZT. Measures of insulin sensitivity. Clin Lab Med 2006;26: , vi. 6. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126: Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38: Monto A, Alonzo J, Watson JJ, et al. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002;36: Hwang SJ, Luo JC, Chu CW, et al. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol 2001;16: Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33: Lonardo A, Adinolfi LE, Loria P, et al. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004;126: Romero-Gomez M, Del MV, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: D Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005;100: Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28: Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287: Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108: Zein CO, Levy C, Basu A, et al. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol 2005;100: Zein NN, Abdulkarim AS, Wiesner RH, et al. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol 2000; 32: Camma C, Bruno S, Di MV, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006;43: Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med 2002;19: Camma C, Bruno S, Di Marco V, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006;44: Lonardo A, Loria P, Adinolfi LE, et al. Hepatitis C and steatosis: a reappraisal. J Viral Hepat 2006;13: Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33: Alsatie M, Kwo PY, Gingerich JR, et al. A multivariable model of clinical variables predicts advanced fibrosis in chronic hepatitis C. J Clin Gastroenterol 2007;41: Papatheodoridis GV, Chrysanthos N, Savvas S, et al. Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepat 2006; 13: Noto H, Raskin P. Hepatitis C infection and diabetes. J Diabetes Complications 2006;20: Ratziu V, Munteanu M, Charlotte F, et al. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003;39: Hickman IJ, Powell EE, Prins JB, et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003;39: Fartoux L, Chazouilleres O, Wendum D, et al. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005;41: Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27: Address requests for reprints to: Nizar N. Zein, MD, Department of Gastroenterology and Hepatology, Cleveland Clinic Foundation, Mail Code: A30, 9500 Euclid Avenue, Cleveland, Ohio Zeinn@ccf.org; fax: (216)
Steatosi epatica ed HCV
Steatosi epatica ed HCV Malattie delle vie biliari ed Epatologia Rho, Auditorium Padri Oblati, 11 Novembre 2006 Piero L. Almasio Università di Palermo HISTOPATHOLOGY Steatosis and accelerated fibrogenesis:
More informationTreatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.
Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationThe treatment of choice for chronic hepatitis C is
Early Identification of HCV Genotype 1 Patients Responding to 24 Weeks Peginterferon -2a (40 kd)/ribavirin Therapy Donald M. Jensen, 1 Timothy R. Morgan, 2 Patrick Marcellin, 3 Paul J. Pockros, 4 K. Rajender
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationةي : لآا ةرقبلا ةروس
سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a
More informationCurrent therapy for hepatitis C: pegylated interferon and ribavirin
Clin Liver Dis 7 (2003) 149 161 Current therapy for hepatitis C: pegylated interferon and ribavirin John G. McHutchison, MD a, Michael W. Fried, MD b, * a Duke Clinical Research Institute, Duke University
More informationAnumber of studies have demonstrated a strong association
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:458 462 Reduction of Insulin Resistance With Effective Clearance of Hepatitis C Infection: Results From the HALT-C Trial AYMIN DELGADO BORREGO,* SERGIO H.
More informationOver the past decade, the introduction of
MANAGEMENT OF CHRONIC HEPATITIS C IN HIV-INFECTED PATIENTS: CLINICAL EXPERIENCE WITH PEGYLATED INTERFERON α PLUS RIBAVIRIN Raymond T. Chung, MD* ABSTRACT Coinfection with hepatitis C virus (HCV) is common
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationCHRONIC HCV TREATMENT: In Special Populations.
CHRONIC HCV TREATMENT: In Special Populations. By Taher EL-ZANATY Prof. of Internal Medicine CAIRO UNIVERSITY Introduction: HCV is the major cause of chronic hepatitis in Egypt. Its end stage is liver
More informationPegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience
Pegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience E L Seow, PH Robert Ding Island Hospital, Penang, Malaysia. Introduction Hepatitis
More informationMETABOLIC SYNDROME AND HCV: FROM HCV
METABOLIC SYNDROME AND HCV: FROM THEORY TO PRACTICE HCV Steatosis Insulin resistance Arun J Sanyal M.D. Chairman, Div. of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University Richmond,
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C
More informationThe Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University
The Effect of Antiviral Therapy on Liver Fibrosis in CHC Jidong Jia Beijing Friendship Hospital, Capital Medical University 2016-5-29 1 Disclosure Consultation for Abbvie, BMS, Gilead, MSD, Novartis and
More informationSafety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus
Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationJournal of American Science, 2012;8(4)
Diabetes Mellitus and peripheral Insulin Resistance in Egyptian Chronic HCV Patients Treated with Standard Antiviral Therapy Amal S. Bakir, Kadry M Elsaeed, Marcel W. Keddeas Faculty of Medicine, Ain Shams
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationReviews/Evaluations. Chronic Hepatitis C. Introduction and Epidemiology. Natural Course of HCV. Recommendations for Treatment
Reviews/Evaluations Chronic Hepatitis C Introduction and Epidemiology Hepatitis C virus (HCV) is one of the most common blood-borne infections and cause of chronic liver disease in the United States (1).
More informationThe medical management of hepatitis C
CLINICAL EXPERIENCE WITH PEGYLATED INTERFERON α-2a PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C VIRUS INFECTION IN PATIENTS INFECTED WITH HIV: THE APRICOT STUDY Douglas T. Dieterich, MD* ABSTRACT Currently,
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationT he hepatitis C virus (HCV) is a major cause of chronic
1638 VIRAL HEPATITIS Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C T Asselah, N Boyer, M-C Guimont, D Cazals-Hatem, F Tubach, K
More informationAnemia in the Treatment of Hepatitis C Virus Infection
SUPPLEMENT ARTICLE Anemia in the Treatment of Hepatitis C Virus Infection Mark S. Sulkowski Center for Viral Hepatitis, Johns Hopkins University, Baltimore, Maryland Hepatitis C virus (HCV) infection is
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationLa sindrome metabolica e il suo impatto dopo la guarigione nel paziente HIV/HCV
WORKSHOP HCV: la guarigione e il parallelismo tra risposta virologica sostenuta e outcome clinico Milano, 25 Ottobre 2018 Ospedale San Raffaele IRCCS - Sede Turro La sindrome metabolica e il suo impatto
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More informationPoor response to hepatitis C treatment in elderly patients
392 ORIGINAL ARTICLE May-June, Vol. 12 No.3, 2013: 392-398 Poor response to hepatitis C treatment in elderly patients Ivonete Silva, Roberto Carvalho Filho, Ana Cristina Feldner, Iandra Zaros, Antonio
More informationPRACTICE GUIDELINES INTRODUCTION
American Journal of Gastroenterology ISSN 0002-9270 C 2006 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2006.00754.x Published by Blackwell Publishing PRACTICE GUIDELINES Management and Treatment
More informationScottish Medicines Consortium
Scottish Medicines Consortium pegylated interferon α 2b (ViraferonPeg ), 50, 80, 100, 120 or 150 micrograms powder for solution for injection in pre-filled pen, in combination with ribavirin (Rebetol ),
More informationLaboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011
Laboratory analysis of the obese child recommendations and discussion MacKenzi Hillard May 4, 2011 aka: What to do with Fasting Labs The Obesity Epidemic The prevalence of obesity in adolescents has tripled
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationH epatitis C virus (HCV) is a major cause of chronic liver
89 LIVER AND BILIARY DISEASE Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C I J Hickman, A D Clouston, G A Macdonald, D M Purdie, J B Prins, S Ash,
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Sovaldi (sofosbuvir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/8/2014 1. Indications Drug Name: Sovaldi
More informationV.G. Bain, P. Marotta, K. Kaita, E. Yoshida, M. Swain, R. Bailey, A. Neumann, P. Cronin, J. McHutchison, E. Pulkstenis, M.
COMPARABLE ANTIVIRAL RESPONSE RATES WITH ALBINTERFERON ALFA-2B DOSED AT Q2W OR Q4W INTERVALS IN NAIVE SUBJECTS WITH GENOTYPE 2 OR 3 CHRONIC HEPATITIS C V.G. Bain, P. Marotta, K. Kaita, E. Yoshida, M. Swain,
More informationC hronic infection with the hepatitis C virus (HCV) is a
406 LIVER Steatosis affects chronic hepatitis C progression in a genotype specific way L Rubbia-Brandt, P Fabris, S Paganin, G Leandro, P-J Male, E Giostra, A Carlotto, L Bozzola, A Smedile, F Negro...
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationAssessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.3.203 Assessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C Jung Hyun Kwon
More informationIL METABOLISMO EPATICO DEI CARBOIDRATI IN FISIOLOGIA E PATOLOGIA
UNIGASTRO Il fegato come centrale metabolica e i fattori di danno oltre ai virus epatitici IL METABOLISMO EPATICO DEI CARBOIDRATI IN FISIOLOGIA E PATOLOGIA Dr Elisabetta Bugianesi Divisione di Gastro-Epatologia
More information554 BJID 2007; 11 (December)
554 BJID 2007; 11 (December) Using Pegylated Interferon alfa-2b and Ribavirin to Treat Chronic Hepatitis Patients Infected with Hepatitis C Virus Genotype 1: Are Nonresponders and Relapsers Different Populations?
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationDeterminants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus
Determinants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus Leah Burke, M.D. 1, Daniel Fierer, M.D. 2, David Cassagnol,
More informationL iver steatosis is a frequent histological finding in patients
420 LIVER Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis L Castéra, C Hézode,
More informationHepatitis C Update. Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011
Hepatitis C Update Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011 Outline n Educational Objectives Epidemiology and Natural History of Hepatitis C Current Treatment
More informationProspective Analysis of Patient Education Time and Administration Errors Associated with Administration of Pegasys versus Peg-Intron
Prospective Analysis of Patient Education Time and Administration Errors Associated with Administration of Pegasys versus Peg-Intron David Finkelman, MD, MBA Janet McRea, LPN Reprint requests to: David
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio
More informationYun Jung Kim, Byoung Kuk Jang, Eun Soo Kim, Kyung Sik Park, Kwang Bum Cho, Woo Jin Chung, and Jae Seok Hwang
The Korean Journal of Hepatology 2012;18:41-47 http://dx.doi.org/10.3350/kjhep.2012.18.1.41 pissn: 1738-222X eissn: 2093-8047 Original Article Rapid normalization of alanine aminotransferase predicts viral
More informationSupplementary Table 1. The distribution of IFNL rs and rs and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC
Supplementary Table 1. The distribution of IFNL rs12979860 and rs8099917 and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC rs12979860 (n=3129) CC 1127 1145.8 CT 1533 1495.3 TT
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationPrevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar
Original Research Article Prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar Naresh Kumar 1, Jyoti Kumar Dinkar 2*, Chandrakishore
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationInsulin resistance is extremely common; frequently is associated STATE OF THE ART
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:864 876 STATE OF THE ART Insulin Resistance Among Patients With Chronic Hepatitis C: Etiology and Impact on Treatment STEPHEN A. HARRISON Division of Gastroenterology
More informationPretreatment assessment of Chronic Hepatitis C and Compensated Cirrhosis and Indications for Therapy
Pretreatment assessment of Chronic Hepatitis C and Compensated Cirrhosis and Indications for Therapy Teerha Piratvisuth MD. Prince of Songkla University Treatment of chronic hepatitis C and response rates
More informationIntravenous drug use is currently the main transmission
A Prospective Controlled Study of Interferon-Based Therapy of Chronic Hepatitis C in Patients on Methadone Maintenance Stefan Mauss, 1 Florian Berger, 1 Joerg Goelz, 2 Bernhard Jacob, 3 and Günther Schmutz
More information2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-333 Volume: Name of Active Ingredient: Page: Sodium N-{6-[3-tert-butyl-5-(2,4-
More informationThe impact of the treatment of HCV in developing Hepatocellular Carcinoma
The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationImproving Treatment Success Rates for HCV in a Managed Care Setting
Improving Treatment Success Rates for HCV in a Managed Care Setting Bruce R. Bacon, MD James F. King MD Endowed Chair in Gastroenterology Professor of Internal Medicine Division of Gastroenterology and
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, 2014 ClinicalTrials.gov ID: NCT00372385 Study Identification Unique Protocol ID: VX05-950-104EU Brief Title:
More informationASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT
ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT Mitchell L Shiffman, MD Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationOptimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:610 615 Optimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection YOAV LURIE,* REGINE ROUZIER PANIS, GEORGE
More informationHCV care after cure. This program is supported by educational grants from
HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico
More informationA COMPARATIVE ANALYSIS OF SERUM LIPIDS IN PATIENTS WITH CHRONIC HEPATITIS C, NONALCOHOLIC FATTY LIVER DISEASE AND HEALTHY CONTROLS
10.1515/AMB-2017-0001 ORIGINAL ARTICLES A COMPARATIVE ANALYSIS OF SERUM LIPIDS IN PATIENTS WITH CHRONIC HEPATITIS C, NONALCOHOLIC FATTY LIVER DISEASE AND HEALTHY CONTROLS I. Valkov 1,4, R. Ivanova 2,4,
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationAntiviral therapy guidelines for the general population
Discussion 10 Chapter 10 Hepatitis C a worldwide problem More than 170 million people worldwide suffer from chronic hepatitis C. Its prevalence is 2% in industrialized countries. 1 Approximately 20% of
More informationWaseem Hamoudi MD*, Sami Al-Smadi MD*, Karim Lutfi MD*, Moath Azizi MD*, Yousef Niomat MD* ABSTRACT
Durability of Sustained Virological Response and Long Term Follow Up To Pegylated Interferon and Ribavirin in Treated Patients with Chronic Hepatitis C Waseem Hamoudi MD*, Sami Al-Smadi MD*, Karim Lutfi
More informationClearance of HCV by Combination Therapy of Pegylated Interferon α-2a and Ribavirin Improves Insulin Resistance
Gut and Liver, Vol. 3, No. 2, June 2009, pp. 108-115 original article Clearance of HCV by Combination Therapy of Pegylated Interferon α-2a and Ribavirin Improves Insulin Resistance Hong Joo Kim, Jung Ho
More informationCurrent Standard of Care for Naïve HCV Patients (SVR)
Hepatitis C: Non-responders Nikunj Shah, MD Associate Professor of medicine University of Illinois Medical center 1 Current Standard of Care for Naïve HCV Patients (SVR) 1 8 8 6 53 45 4 6 52 46 4 2 2 Peg
More informationAbstract and Introduction. Patients and Methods. M. Hedenstierna; A. Nangarhari; A. El-Sabini; O. Weiland; S.
www.medscape.com Cirrhosis, High Age and High Body Mass Index Are Risk Factors for Persisting Advanced Fibrosis After Sustained Virological Response in Chronic Hepatitis C M. Hedenstierna; A. Nangarhari;
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationConventional Interferon Alfa-2b and Ribavirin for 12 Versus 24 Weeks in HCV Genotype 2 or 3
ORIGINAL ARTICLE Conventional Interferon Alfa-2b and Ribavirin for 12 Versus 24 Weeks in HCV Genotype 2 or 3 Javed Iqbal Farooqi and Rukhsana Javed Farooqi* ABSTRACT Objective: To determine the efficacy
More informationManagement of Incidental Hepatitis C Virus Infection
The new england journal of medicine Clinical Decisions Interactive at nejm.org Management of Incidental Hepatitis C Virus Infection This interactive feature addresses the diagnosis or management of a clinical
More informationMeet the Professor: HIV/HCV Coinfection
Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University
More informationHepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona
Hepatitis C: New Antivirals in the Liver Transplant Setting Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Patient survival Hepatitis C and Liver Transplantation Years after transplantation
More informationPrise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques
Prise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques Future Complications of Darius Moradpour Service de Gastro-entérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois
More informationVisceral Adiposity Index Is Associated with Histological Findings and High Viral Load in Patients with Chronic Hepatitis C Due to Genotype 1
Visceral Adiposity Index Is Associated with Histological Findings and High Viral Load in Patients with Chronic Hepatitis C Due to Genotype 1 Salvatore Petta, 1 Marco Amato, 2 Daniela Cabibi, 3 Calogero
More informationFollow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France
9th Paris Hepatitis Conference, January 11-12, 2016 Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France Disclosures
More informationLiver Transplantation: The End of the Road in Chronic Hepatitis C Infection
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2012 UMass Center for Clinical and Translational Science Research Retreat
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationHepatitis C wi w t i h Ju J dy y W y W a y t a t t
Hepatitis C with Judy Wyatt Hepatitis C and the histopathologist Pre-2006 biopsy based treatment of moderate-severe chronic hepatitis Now biopsy for: Watchful waiting, to confirm mild disease? Cirrhosis
More informationImpatto della clearance virale e rischio di carcinoma epatocellulare
EPATITE CRONICA DA HCV: Impatto della clearance virale e rischio di carcinoma epatocellulare Rodolfo Sacco, M.D., PhD Direttore U.O.C. Gastroenterologia ed Endoscopia Digestiva A.O.U. Ospedali Riuniti"
More informationPegylated Interferon Agents for Hepatitis C
Applicable X X X X X X X Pegylated Interferon Agents for Hepatitis C Override(s) Prior Authorization Quantity Limit Initial for Monotherapy or Combination with Ribavirin based on Genotype, Status, or Co-Infection
More informationTratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona
Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona rrent HCV Therapy 8% % sustained response 6% 4% 2% % 54-61% 41% 34% 25% 16% 6% IFN 24w IFN 48w Peg
More informationUNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS PHARMACOGENETICS AND THE APPLICATION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN RESPONSE TO PEGYLATED INTERFERON AND RIBAVIRIN
More information3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H.
U.S. Adults: 1988 Nineteen states with 10-14% 14% Prevalence of Obesity (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Metabolic John P. Cello, MD Professor of Medicine and Surgery, University of California,
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationReferring to Part of Dossier: Volume: Page:
Synopsis AbbVie Inc. Name of Study Drug: ABT-450, ritonavir, ABT-333, ribavirin Name of Active Ingredient: ABT-450: (2R,6S,12Z,13aS,14aR,16aS)-N- (cyclopropylsulfonyl)-6-{[(5- methylpyrazin-2-yl)carbonyl]amino}-
More informationReview Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3
Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3 Thomas Berg 1 * and Giampiero Carosi 2 Antiviral Therapy 13 Suppl 1:17 22 1 Charite Universitatsmedizin Berlin, Berlin, Germany
More informationMetabolic Syndrome: What s in a name?
Commentary Metabolic Syndrome: What s in a name? Deborah P. Wubben, MD, MPH; Alexandra K. Adams, MD, PhD Abstract The term metabolic syndrome has recently become en vogue. But is the definition realistic,
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationTreatment of chronic hepatitis D patients with pegylated interferon: a real world experience
Treatment of chronic hepatitis D patients with pegylated interferon: a real world experience Zaigham Abbas, Mohammad Sadik Memon, Hammad Mithani, Wasim Jafri, Saeed Hamid Antiviral Therapy 2014; 10.3851/IMP2728
More informationO riginal Article INTRODUCTION ABSTRACT
O riginal Article Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection Mona H. Ismail Department of
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationBody Mass Index and Nonresponse to Antiviral Treatment in Korean Patients with Genotype 2 and 3 Chronic Hepatitis C
Original Article-Infection and immunology www.cmj.ac.kr Body Mass Index and Nonresponse to Antiviral Treatment in Korean Patients with Genotype 2 and 3 Chronic Hepatitis C Yeon Joo Kim, Sung Bum Cho, Sang
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy
More informationOver the last 2 years exciting novel pharmacogenetic
Clinical Utility of Interleukin-28B Testing in Patients With Genotype 1 Michelle Lai and Nezam H. Afdhal See Editorial on Page 5 Over the last 2 years exciting novel pharmacogenetic data have emerged on
More information